NClip

Dealing with Addiction

7 min read

Dealing with Addiction

Key Points

  • Effective addiction care uses a continuum from early intervention to treatment and long-term recovery support.
  • Medication-assisted treatment combines pharmacotherapy with behavioral care and improves retention and outcomes.
  • Withdrawal stabilization is medically important but is not a complete treatment for substance use disorder.
  • Collaborative, nonjudgmental care lowers relapse and overdose risk after detox.
  • Detox follow-through is a major risk point; many clients never enter continuing treatment without active linkage support.
  • Behavioral compulsive-use patterns (for example excessive screen/social-media/gaming exposure) can worsen sleep, concentration, anxiety, and depressive symptom burden in emerging adults.

Pathophysiology

Addiction reflects chronic neurobehavioral dysregulation affecting reward, stress response, and executive control. Acute withdrawal destabilizes multiple physiologic systems and can become life-threatening in alcohol or benzodiazepine dependence.

Post-detox periods are high risk because tolerance decreases. If a person returns to previous doses, overdose risk rises substantially, especially with opioids.

Treatment outcomes improve when SUD is managed as a chronic condition (similar to hypertension or diabetes) with sustained evidence-based care, supportive monitoring, and coordinated social support instead of a single short episode of care.

Classification

  • Early intervention stage: Screening, brief intervention, guided self-change.
  • SBI/SBIRT stage: Structured screening plus brief intervention and referral to specialty treatment when indicated.
  • Active treatment stage: Detox/stabilization, medication, psychotherapy, structured programming.
  • Recovery support stage: Peer/community supports, relapse prevention, long-term follow-up.
  • Stepped-intensity continuum: Inpatient withdrawal management, residential treatment, partial hospitalization/intensive outpatient, then lower-intensity outpatient self-management support.
  • Withdrawal-to-treatment gap: Many clients disengage after detoxification alone; reports commonly cite that up to about three-quarters do not enter continuing treatment without active linkage.
  • Chronic-care framing: Relapse can occur and does not equal treatment failure; plan revisions and sustained supports are expected.
  • Recovery-definition framing: Abstinence is important but recovery also includes improved health, function, and self-directed living.
  • ROSC framing: Recovery-oriented systems of care use long-term monitoring (for example checkups/case monitoring), recovery housing, and recovery coaching to reduce relapse burden.
  • Behavioral-use risk stage: Non-substance reward-loop behaviors with variable-reward reinforcement and impaired self-limiting control.

Nursing Assessment

NCLEX Focus

Determine whether the client needs emergency overdose care, acute withdrawal stabilization, or step-down recovery support.

  • Assess substance history, current symptoms, and immediate medical risk.
  • Assume use history may be underreported and include collateral cues from current symptoms, family reports, and objective clinical findings.
  • Assess overdose signs by substance type (opioid, stimulant, alcohol, medication ingestion).
  • Assess withdrawal trajectory, severity, and complication risk (seizure, delirium, autonomic instability).
  • Use structured withdrawal tools by substance (for example CIWA-Ar for alcohol and COWS for opioids) to support protocol-based dosing and reassessment.
  • Assess stage of readiness for change (precontemplation to maintenance).
  • In general-care settings (for example primary care, obstetrics-gynecology, emergency, and medical-surgical units), maintain high suspicion for undiagnosed SUD and screen early.
  • Use validated screening tools in routine care workflows (for example AUDIT for alcohol) and escalate from screening to brief intervention/referral based on risk severity.
  • Assess treatment-access barriers directly (readiness, cost/insurance, stigma/job impact concerns, transportation, and treatment-program fit).
  • Assess readiness-for-change stage explicitly (precontemplation, contemplation, preparation, action, maintenance) and match teaching intensity to the stage.
  • In younger adults, assess daily screen/gaming/social-media exposure pattern and timing when insomnia, inattention, or mood decline is present.
  • Assess co-occurring mental-health conditions and their effect on treatment engagement/retention.
  • Assess infectious-disease risk in ongoing misuse contexts (for example HIV, hepatitis B/C, tuberculosis exposure risk) and readiness for prevention counseling/testing.
  • Assess support network, housing, insurance access, and treatment continuity barriers.

Nursing Interventions

  • Deliver rapid overdose response: stimulation check, emergency activation, airway support/resuscitation, and opioid reversal with repeat naloxone dosing every 2-3 minutes when needed.
  • Use poison-control or bedside toxicology consultation early for uncertain or mixed ingestions to refine antidote and monitoring plans.
  • In suspected alcohol overdose, protect airway and use side-lying or partially upright positioning for unresponsive clients to reduce aspiration risk.
  • Arrange urgent transfer for monitored medical care even if early naloxone response appears adequate.
  • Use validated withdrawal protocols and frequent reassessment for symptom-guided treatment.
  • Apply SBIRT sequence when indicated: screen in routine care, deliver nonjudgmental brief intervention, then complete active referral when disorder severity or failed brief response requires specialty care.
  • Use brief quit-coaching structure when appropriate: set a quit date, remove triggers from the environment, practice urge-distraction techniques, review prior quit attempts, and build a support network.
  • Provide education on relapse risk after detox and individualized safety planning.
  • Frame detoxification clearly as a stabilization step, then secure rapid transition to ongoing treatment because disengagement after withdrawal management is common.
  • Build retention plans around chronic-care timelines; many clients need at least about 3 months of active treatment, and severe SUD commonly requires around 1 year of staged engagement across settings.
  • Reinforce that treatment can still be effective even when initially externally motivated (for example family, work, or legal pressure), then shift toward internal motivation over time.
  • For compulsive screen-use patterns, teach trial behavior plans (use diary, pre-sleep device cut-off, and structured replacement activities) and monitor symptom response.
  • Coordinate discharge across inpatient, residential, community, IOP, and peer-support options.
  • Link clients to recovery support services (mutual aid groups, recovery coaches, recovery housing, and community/education-based recovery programs) to improve long-term remission stability.
  • Include client and family peer-network options (for example AA/NA, Nar-Anon/Al-Anon, NAMI pathways, and veteran-focused supports when applicable) with face-to-face or virtual access plans.
  • Provide crisis-escalation access teaching (U.S. 988) for acute mental-health or substance-related crisis moments.
  • Use harm-reduction interventions for clients not yet ready for abstinence (for example overdose-prevention education, naloxone access, and safer-use infection-risk reduction services) while keeping treatment pathways open.
  • Coordinate infectious-disease screening and risk-reduction counseling within SUD treatment plans.
  • Use culturally responsive, trauma-informed, stigma-free communication in all encounters.
  • Use person-first, non-stigmatizing language and correct myths that frame SUD as moral failure or lack of willpower.

Detox Alone Is Insufficient

Withdrawal management without follow-up treatment has high relapse and overdose risk.

Pharmacology

MAT medications include buprenorphine-naloxone, methadone, and naltrexone for opioid-related disorders. Buprenorphine-naloxone is commonly used for detoxification or maintenance; methadone used for OUD is a Schedule II medication dispensed through SAMHSA-certified and state-approved opioid treatment programs. Naltrexone is not scheduled and extended-release injection formulations can improve relapse prevention adherence.

AUD medications include naltrexone, acamprosate, and disulfiram; selected clients also require nutritional repletion such as thiamine and magnesium.

Nicotine-use treatment can include nicotine-replacement therapies (patch, gum, lozenge, spray) or oral options such as bupropion or varenicline when integrated with behavioral treatment.

Alcohol withdrawal uses benzodiazepines as first-line therapy for seizure and delirium-tremens prevention and may require thiamine/electrolyte correction; severe cases can require ICU-level care. Dexmedetomidine may be used as an adjunct for sympathetic overactivity in ICU settings but does not treat withdrawal seizures. Nurses monitor blood pressure, sedation level, respiratory status, renal risk, and medication response.

For opioid withdrawal, first-line treatment commonly uses buprenorphine when withdrawal is objectively present; methadone may be used with careful monitoring because overdose risk remains clinically significant. Alpha-2 adrenergic agonists such as clonidine or lofexidine can reduce autonomic withdrawal symptoms.

Symptom-targeted detox medication bundles are commonly used (for example headache, GI upset, diarrhea, rhinorrhea, anxiety, and blood-pressure elevation support), with nursing reassessment after each dose. For clonidine-based support, monitor blood pressure trend, sedation burden, and renal-risk context closely.

Benzodiazepine withdrawal can be life-threatening and may include agitation, hallucinations, psychosis, seizures, and autonomic instability. Management typically substitutes a long-acting benzodiazepine and uses a slow individualized taper (often about 10-25% dose reduction every 1-2 weeks) to reduce severe withdrawal complications.

Nonpharmacologic treatment remains essential: motivational interviewing, behavioral therapies, contingency-management incentives, family/group counseling, 12-step programs, and recovery-support services that remove practical barriers to sustained care.

Clinical Judgment Application

Clinical Scenario

A client completes inpatient detox and reports strong cravings, low confidence, and uncertain follow-up plans.

  • Recognize Cues: Reduced tolerance, high craving, and weak post-discharge supports.
  • Analyze Cues: Immediate relapse and overdose risk is high without continuity planning.
  • Prioritize Hypotheses: Priority is safe transition with treatment engagement.
  • Generate Solutions: Arrange MAT follow-up, counseling, peer support, and crisis contacts.
  • Take Action: Finalize coordinated discharge plan with family/team education.
  • Evaluate Outcomes: Verify appointments, support activation, and client understanding of relapse response.

Graph View